Ruxotinib / 100mg
Properties
| Density | 1.4 g/ml |
| Melting Point | 86-89° C |
Product Description
Ruxolitinib is a potent and selective JAK1/2 inhibitor, known for its high selectivity over JAK3, which is crucial for its therapeutic efficacy. It has been extensively studied for its potential in treating various conditions, particularly in the field of oncology and hematology. The innovativeness of Ruxolitinib stems from its mechanism of action, which includes the induction of autophagy and the subsequent killing of tumor cells through a process known as mitophagy, a form of selective cell death that is highly specific to cancer cells. This mechanism of action not only targets cancer cells more effectively than traditional chemotherapy but also reduces the side effects associated with chemotherapy, such as damage to healthy cells and hair loss.
Ruxolitinib is FDA approved for the treatment of myelofibrosis and polycythemia vera, conditions characterized by abnormal blood clotting and excessive production of red blood cells, respectively. Its effectiveness in these treatments is attributed to its ability to inhibit the JAK/STAT signaling pathway, which plays a critical role in the proliferation and survival of these blood cells.
Articles:
-Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
Publication Date:15 Sep 2011
Alen Ostojic, Radovan Vrhovac and Srdan Verstovsek
https://doi.org/10.2217/fon.11.81
-A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
Publication Date: DECEMBER 30, 2021
Alison J. Moskowitz, Paola Ghione, Eric Jacobsen, Jia Ruan, Jonathan H. Schatz, Sarah Noor, Patricia Myskowski, Santosha Vardhana, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Alayna Santarosa, Jack Dowd, Obadi Obadi, Lauren Pomerantz, Nancy Yi, Samia Sohail, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Jeeyeon Baik, Mark B. Geyer, Ariela Noy, David Straus, Priyadarshini Kumar, Ahmet Dogan, Travis Hollmann, Esther Drill, Jurgen Rademaker, Heiko Schoder, Giorgio Inghirami, David M. Weinstock, Steven M. Horwitz
https://doi.org/10.1182/blood.2021013379
-The Role of JAK1/2 Inhibitors in the Treatment of Chronic Myeloproliferative Neoplasms
Publication Date: May 16, 2013
Clodagh Keohane, Ruben Mesa and Claire Harrison